Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model

Generic cardiology drug prices: the potential benefits of the Marc Cuban cost plus drug company model

Introduction: Generic pharmaceuticals account for the majority of the $359 billion US pharmaceutical market, including for cardiology drugs. Amidst a lack of price transparency and administrative inefficiencies, generic drug prices are high, causing an undue burden on patients.Methods: We identified...

Full description

Bibliographic Details
Main Authors: Aparna Narendrula, Jacob Lang, Elias Mossialos
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Pharmacology
Subjects:
cardiology
generic pharmaceuticals
drug prices
health policy
United States
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1179253/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1179253/full

Similar Items